[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622924":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":21,"interventions":32,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":38,"collaborators":11,"id":42,"slug":11,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":11,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":11},{"fullName":5,"class":6},"University of Luebeck","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Freedom from atrial arrhythmia (AF\u002Fatrial flutter\u002Fatrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period)",null,"12 months",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"SINGLE",[20],"OUTCOMES_ASSESSOR",[22,28],{"label":23,"type":24,"description":25,"interventionNames":26},"Catheter ablation for atrial fibrillation plus semaglutide","EXPERIMENTAL","Catheter ablation for atrial fibrillation plus semaglutide (up to 2.4 mg weekly)",[27],"Drug: Semaglutide (SEMA)",{"label":29,"type":30,"description":31,"interventionNames":11},"Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy","NO_INTERVENTION","Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy (standard therapy)",[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"DRUG","Semaglutide (SEMA)","Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)",[23],{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Roland Richard Tilz, MD","Director, Department of Rhythmology","100622924",false,"NCT07389941","Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation","Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)","SPICE-AF","Inclusion criteria:\n\n* Age 18-80 years\n* Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation\n* Body mass index ≥30 kg\u002Fm or body mass index ≥28 kg\u002Fm plus ≥1 weight-related comorbidity\n* No prior treatment with glucacon-like peptide-1 receptor agonists\n\nExclusion criteria:\n\n* Current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening\n* Current antiobesity medication use or use within the last 90 days prior to screening\n* A self-reported change in body weight of \\>5 kg within 30 days before screening\n* History of bariatric surgery\n* History of diabetes mellitus\n* Hospitalization for unstable angina, or transient ischemic attack \\\u003C30 days prior to screening\n* Pulmonary embolism \\\u003C90 days before screening\n* Myocardial infarction, or stroke \\\u003C90 days prior to screening\n* Uncontrolled thyroid disease: thyroid-stimulating hormone \\>10.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL at screening\n* Active malignancy\n* Acute pancreatitis \\\u003C180 days before screening\n* History or presence of chronic pancreatitis\n* Chronic kidney disease with creatinine clearance \\\u003C30 mL\u002Fmin\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n* Chronic inflammatory conditions requiring immunosuppression and\u002For on glucocorticoids\n* Pregnancy, breast-feeding or planning pregnancy","ALL","18 Years",{"count":52,"type":53},240,"ESTIMATED","INTERVENTIONAL",[56],"PHASE4","To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.",[59],"Atrial Fibrillation (AF)","NOT_YET_RECRUITING","2026-02-08",{"date":63,"type":64},"2026-02-11","ACTUAL",{"date":66,"type":53},"2026-10",{"date":68,"type":53},"2029-04",{"name":5,"class":6}]